Amgen Ventures and Business Development Team

Amgen Ventures and Business Development Team

11-01-2017 1:30 pm - 11-01-2017 3:00 pm

To apply for Office Hours, please contact Linda Eng.

Janis Naeve, Ph.D. joined Amgen in 2005 and is the Managing Director of Amgen Ventures, guiding the fund’s investment in biotechnology companies focused on discovering and developing human therapeutics. From 2002 to 2005, Dr. Naeve was director of Corporate Development at X-Ceptor Therapeutics, acquired by Exelixis. Prior to this, she served as director of Business Development at Aurora Biosciences, leading transactions for the ion channel technology business unit and managing collaborations with Pfizer, Merck, Lilly and Bristol Myers-Squibb. Dr. Naeve holds a Ph.D. in Pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.
Alex Turner, Ph.D. joined Amgen in 2012 and is a Licensing Director, leading search and evaluation of product opportunities for Amgen’s Neuroscience, Nephrology, and Bone Health therapeutic areas. Prior to Amgen, Dr. Turner was Senior Director of Business Development at Lexicon Pharmaceuticals, leading out-licensing outreach across the company’s pipeline and in-licensing search and evaluation of technologies to accelerate drug discovery. Dr. Turner holds a Ph.D. in Microbiology and Immunology from Stanford University and completed a post-doctoral fellowship at Boston Children’s Hospital.
Becky Pferdehirt, Ph.D. joined Amgen in 2016 and is a Senior Manager of Business Development, focusing on licensing of external technology platforms to support Amgen’s R&D. Prior to joining Business Development, Becky was a scientist in Discovery Research at Amgen, focusing on technology development for gene and cell therapies. Dr. Pferdehirt holds a Ph.D. in Molecular and Cellular Biology from U.C. Berkeley and completed a post-doctoral fellowship at Genentech.

Related upcoming events

  • 12-14-2017 2:00 pm - 12-14-2017 3:30 pm

    1. HPLC Products
    2. Business Development and Venture Investment

    Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them.

    Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering.

    Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry.

    Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

qb3at953 News

Upcoming Event

  • Tosoh Hour

    14:00-15:30
    12/14/2017
    1. HPLC Products 2. Business Development and Venture Investment Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them. Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering. Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry. Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter